Molly M Foote1, Milo Careaga2, Robert F Berman3. 1. a Department of Neurological Surgery , University of California Davis , Davis , CA , USA. 2. b Department of Psychiatry and UC Davis M.I.N.D. Institute , University of California Davis , Davis , CA , USA. 3. c Department of Neurological Surgery and the UC Davis M.I.N.D. Institute , University of California Davis , Davis , CA , USA.
Abstract
OBJECTIVE: To describe in this review how research using mouse models developed to study the Fragile X premutation (PM) and Fragile X-associated tremor/ataxia syndrome (FXTAS) have contributed to understanding these disorders. PM carriers bear an expanded CGG trinucleotide repeat on the Fragile X Mental Retardation 1 (FMR1) gene, and are at risk for developing the late onset neurodegenerative disorder FXTAS. CONCLUSIONS: Much has been learned about these genetic disorders from the development and study of mouse models. This includes new insights into the early cellular and molecular events that occur in PM carriers and in FXTAS, the presence of multiorgan pathology beyond the CNS, immunological dysregulation, unexpected synthesis of a potentially toxic peptide in FXTAS (i.e., FMRpolyG), and evidence that the disease process may be halted or reversed by appropriate molecular therapies given early in the course of disease.
OBJECTIVE: To describe in this review how research using mouse models developed to study the Fragile X premutation (PM) and Fragile X-associated tremor/ataxia syndrome (FXTAS) have contributed to understanding these disorders. PM carriers bear an expanded CGG trinucleotide repeat on the Fragile X Mental Retardation 1 (FMR1) gene, and are at risk for developing the late onset neurodegenerative disorder FXTAS. CONCLUSIONS: Much has been learned about these genetic disorders from the development and study of mouse models. This includes new insights into the early cellular and molecular events that occur in PM carriers and in FXTAS, the presence of multiorgan pathology beyond the CNS, immunological dysregulation, unexpected synthesis of a potentially toxic peptide in FXTAS (i.e., FMRpolyG), and evidence that the disease process may be halted or reversed by appropriate molecular therapies given early in the course of disease.
Entities:
Keywords:
FXTAS; Fragile X mental retardation gene (FMR1); Fragile X mental retardation protein (FMRP); Fragile X premutation (PM); intranuclear inclusions
Authors: J R Brouwer; E Severijnen; F H de Jong; D Hessl; R J Hagerman; B A Oostra; R Willemsen Journal: Psychoneuroendocrinology Date: 2008-05-12 Impact factor: 4.905
Authors: Ali Entezam; Rea Biacsi; Bonnie Orrison; Tapas Saha; Gloria E Hoffman; Ed Grabczyk; Robert L Nussbaum; Karen Usdin Journal: Gene Date: 2007-03-16 Impact factor: 3.688
Authors: Ronald A M Buijsen; Chantal Sellier; Lies-Anne W F M Severijnen; Mustapha Oulad-Abdelghani; Rob F M Verhagen; Robert F Berman; Nicolas Charlet-Berguerand; Rob Willemsen; Renate K Hukema Journal: Acta Neuropathol Commun Date: 2014-11-26 Impact factor: 7.801
Authors: H Jürgen Wenzel; Karl D Murray; Saif N Haify; Michael R Hunsaker; Jared J Schwartzer; Kyoungmi Kim; Albert R La Spada; Bryce L Sopher; Paul J Hagerman; Christopher Raske; Lies-Anne W F M Severijnen; Rob Willemsen; Renate K Hukema; Robert F Berman Journal: Acta Neuropathol Commun Date: 2019-02-26 Impact factor: 7.801